

Table 19.25
Non-Hodgkin LymphomaEstimated United States Cancer Prevalence Counts^a on January 1, 2013
By Race/Ethnicity, Sex and Years Since Diagnosis

Years Since Diagnosis		0 to <5	5 to <10	10 to <15	15 to <20	20 to <25	25 to <30	0 to <21 ^e	0 to <38 ^e	>=38 ^g	Complete ^h	
Race	Sex											
All Races ^b	Both Sexes	208,024	147,198	93,446	53,791	29,696	17,350	522,304	561,810	7,726	569,536	
	Males	112,213	75,991	48,589	28,402	15,226	9,437	275,343	296,343	4,074	300,417	
	Females	95,811	71,207	44,857	25,389	14,470	7,913	246,961	265,467	3,652	269,119	
White ^b	Both Sexes	177,772	129,114	82,376	47,190	26,689	15,706	454,266	490,081	8,097	498,178	
	Males	96,367	67,062	42,958	24,852	13,724	8,505	240,356	259,429	4,601	264,030	
	Females	81,405	62,052	39,418	22,338	12,965	7,201	213,910	230,652	3,496	234,148	
Black ^b	Both Sexes	17,916	11,753	7,007	4,000	1,905	1,053	41,985	44,379	657	45,036	
	Males	9,210	5,685	3,495	2,144	951	608	21,173	22,442	275	22,717	
	Females	8,706	6,068	3,512	1,856	954	445	20,812	21,937	382	22,319	
Asian/ Pacific Islander ^c	Both Sexes	6,610	4,003	2,560	+	+	+	14,811	+	+	+	
	Males	3,504	2,073	1,331	+	+	+	7,733	+	+	+	
	Females	3,106	1,930	1,229	+	+	+	7,078	+	+	+	
Hispanic ^d	Both Sexes	17,016	10,193	6,238	+	+	+	37,304	+	+	+	
	Males	8,761	5,202	3,274	+	+	+	19,291	+	+	+	
	Females	8,255	4,991	2,964	+	+	+	18,013	+	+	+	

Estimated prevalence percent^a on January 1, 2013, of the SEER^c population diagnosed in the previous 21 years
By Age at Prevalence, Race/Ethnicity and Sex

Age at Prevalence	All Ages	Age Specific (Crude)									Age-Adjusted ^f	
		0-9	10-19	20-29	30-39	40-49	50-59	60-69	70-79	80+	All Ages	
Race	Sex											
All Races ^c	Both Sexes	0.1453%	0.0032%	0.0122%	0.0261%	0.0470%	0.1000%	0.2003%	0.3794%	0.6058%	0.7099%	0.1377%
	Males	0.1555%	0.0042%	0.0166%	0.0316%	0.0550%	0.1164%	0.2326%	0.4283%	0.6806%	0.8179%	0.1581%
	Females	0.1354%	0.0021%	0.0077%	0.0203%	0.0390%	0.0837%	0.1694%	0.3353%	0.5448%	0.6453%	0.1199%
White ^c	Both Sexes	0.1630%	0.0031%	0.0128%	0.0274%	0.0484%	0.1067%	0.2145%	0.4077%	0.6658%	0.7634%	0.1481%
	Males	0.1736%	0.0043%	0.0178%	0.0333%	0.0561%	0.1247%	0.2487%	0.4554%	0.7442%	0.8736%	0.1693%
	Females	0.1524%	0.0020%	0.0077%	0.0211%	0.0402%	0.0881%	0.1806%	0.3632%	0.6002%	0.6968%	0.1290%
Black ^c	Both Sexes	0.0927%	0.0036%	0.0112%	0.0258%	0.0541%	0.0949%	0.1718%	0.2952%	0.3768%	0.3583%	0.1037%
	Males	0.0985%	0.0034%	0.0139%	0.0327%	0.0678%	0.1074%	0.1989%	0.3454%	0.3815%	0.3716%	0.1161%
	Females	0.0875%	0.0038%	0.0083%	0.0191%	0.0421%	0.0839%	0.1482%	0.2560%	0.3735%	0.3517%	0.0932%
Asian/ Pacific Islander ^c	Both Sexes	0.0908%	0.0032%	0.0106%	0.0191%	0.0317%	0.0609%	0.1261%	0.2405%	0.3636%	0.5004%	0.0885%
	Males	0.0983%	0.0046%	0.0132%	0.0216%	0.0355%	0.0679%	0.1475%	0.2748%	0.4244%	0.6218%	0.1037%
	Females	0.0841%	0.0017%	0.0078%	0.0165%	0.0283%	0.0547%	0.1077%	0.2123%	0.3164%	0.4260%	0.0765%
Hispanic ^d	Both Sexes	0.0716%	0.0030%	0.0101%	0.0207%	0.0327%	0.0790%	0.1516%	0.2929%	0.4728%	0.5580%	0.1070%
	Males	0.0729%	0.0034%	0.0131%	0.0248%	0.0385%	0.0890%	0.1702%	0.3041%	0.4833%	0.6015%	0.1155%
	Females	0.0702%	0.0025%	0.0069%	0.0163%	0.0266%	0.0685%	0.1338%	0.2832%	0.4651%	0.5319%	0.0993%

^a US 2013 cancer prevalence counts are based on 2013 cancer prevalence proportions from the SEER registries and 1/1/2013 US population estimates based on the average of 2012 and 2013 population estimates from the US Bureau of the Census. Prevalence was calculated using the First Malignant Primary Only for a person.

^{b c d} Statistics based on (b) SEER 9 Areas (c) SEER 13 Areas excluding the Alaska Native Registry

(d) NHIA for Hispanic for SEER 13 Areas excluding the Alaska Native Registry.

^e Maximum limited-duration prevalence: 38 years for 1975-2013 SEER 9 data; 21 years for 1992-2013 SEER 13 data (excluding the Alaska Native Registry) used to calculate prevalence for Hispanics and Asian Pacific Islanders.

^f Percentages are age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1130) by 5-year age groups.

^{g h i} (g) Cases diagnosed more than 38 years ago were estimated using the completeness index method (Capocaccia et. al. 1997, Merrill et. al. 2000). (h) Complete prevalence is obtained by summing 0 to <38 and >=38. (i) Age-specific completeness index was approximated using empirical data from historical Connecticut tumor registry.

- Statistic not shown. Statistic based on fewer than 5 cases estimated alive in SEER for the time interval.

+ Not available.